HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
Hims & Hers Health (HIMS) rose about 6% intraday before closing up 1.33% after Barclays upgraded its outlook. Barclays raised its HIMS price target to $39 from $29 and kept an Overweight rating, citing accelerating growth tied to Hims & Hers’ Novo Nordisk (NVO) partnership announced March 9. Barclays expects revenue and EBITDA acceleration in 2H 2026.
How this was made
The 30-second read
Why it matters
The key tradable change is Barclays’ higher price target and the thesis that 2H26 revenue and EBITDA should accelerate, potentially prompting a valuation re-rate if the $30 level holds.
Market read
Analyst target hike plus an inflection narrative tied to the Novo partnership is likely to influence near-term positioning and momentum traders in HIMS.
What to watch
The article cites improving trends and back-half acceleration expectations, but provides no new financial print or quantified partnership contribution, leaving execution and timing risk.
Background
Hims & Hers’ March 9 partnership with Novo Nordisk is positioned as a growth catalyst, with Barclays and Morningstar pointing to improving momentum.
Ticker impact
Barclays raised its Hims & Hers price target to $39 from $29 and kept an Overweight rating after citing improving momentum tied to its Novo Nordisk partnership.
Near-term upside bias while traders digest the higher target and the $30 resistance reclaim; follow-through depends on continued evidence of the growth inflection.
The article’s actionable catalyst is a specific analyst target increase plus a thesis that links the Novo partnership to accelerating 2H26 revenue/EBITDA and improving trends from proprietary data.
Market effects
Supports the broader telehealth and weight-loss-adjacent narrative that partnerships can translate into measurable growth inflections.
No clear regional spillover beyond US retail sentiment and analyst coverage.
Limited, as the catalyst is company-specific analyst commentary tied to a Novo Nordisk collaboration.
Counterpoint
The stock’s gains may fade if the “inflection” remains narrative-led and not yet reflected in reported quarterly results.
Key entities
- companyHims & Hers Health
Telehealth company whose shares moved on Barclays’ more bullish stance tied to the Novo Nordisk partnership.
- analyst_firmBarclays
Raised HIMS price target to $39 from $29 and maintained Overweight rating.
- companyNovo Nordisk
Partner referenced as the source of an inflection in Hims & Hers growth trends.
